Stocks · Healthcare · Medical - Devices
Perspective Therapeutics, Inc. CATX
$2.76 +1.47% Close, Oct 2, 2026 · AMEX · Market cap $314.8M
Weak trendExpensive vs sector
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -34216.4% from -16129.1% a year earlier.
- Revenue over the last four quarters was $366,000, down 44.5% from a year earlier, slowing from -17.1% a quarter earlier.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 12%
- Revenue growth accelerationBottom 10%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 38%
- Gross marginBottom 3%
- Operating marginBottom 2%
- Accruals (lower is better)Bottom 47%
- Interest coverBottom 9%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 13%
- Free-cash-flow yieldBottom 12%
- EBITDA / enterprise valueBottom 15%
- Sales / enterprise valueBottom 4%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 30%
- 6-month returnBottom 11%
- 1-year return vs S&P 500Bottom 29%
- Distance from 52-week highBottom 22%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 35%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 38%
- Upside to consensus price targetTop 11%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 39%
- Maximum drawdown, 3 yearsBottom 14%
- Beta vs S&P 500 (lower is better)Bottom 31%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -17.1% | -44.5% | ↓ |
| Gross margin | -112.7% | -419.4% | ↓ |
| Operating margin | -16129.1% | -34216.4% | ↓ |
| FCF margin | -17417.9% | -33111.2% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -44.5% | -17.1% | ↓ | Bottom 12% |
| Gross margin | -419.4% | -112.7% | ↓ | Bottom 3% |
| Operating margin | -34216.4% | -16129.1% | ↓ | Bottom 2% |
| Net margin | -31812.6% | -13945.1% | ↓ | — |
| Free-cash-flow margin | -33111.2% | -17417.9% | ↓ | — |
| Return on invested capital | -34.9% | — | Bottom 38% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -6.0%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 2749.7%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +64.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -410.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -52.27%
- Shareholder yield
- -52.27%
- Share count change, 1 year
- +4.4%
- Share count change, 3-year CAGR
- +38.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 10, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -4.4%
- Average 2-day reaction, last 8
- -0.0%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $11.00
- Target vs current price
- +298.6%
- Analysts with a rating
- 12
- Share rating Buy or Strong Buy
- 83%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 10, 2026 | +12.4% | +0.0% | +6.7% | +4.3% | — |
| May 11, 2026 | +13.8% | +3.2% | +2.4% | -22.1% | -21.8% |
| Mar 16, 2026 | -37.8% | +4.4% | -11.0% | -13.0% | -40.0% |
| Nov 10, 2025 | -6.1% | +1.4% | -5.0% | +9.6% | +111.4% |
| Aug 13, 2025 | +0.0% | -4.3% | -14.1% | -18.8% | -41.5% |
| May 12, 2025 | +10.7% | +6.8% | +11.9% | +37.4% | +62.6% |
| Mar 26, 2025 | -119.2% | -8.1% | -20.6% | -5.7% | +40.1% |
| Nov 12, 2024 | +0.0% | -3.8% | -37.2% | -67.1% | -70.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.22 | -$0.25 | +12.4% | $81,000 |
| May 11, 2026 | -$0.25 | -$0.29 | +13.8% | $76,000 |
| Mar 16, 2026 | -$0.51 | -$0.37 | -37.8% | $43,000 |
| Nov 10, 2025 | -$0.35 | -$0.33 | -6.1% | $209,000 |
| Aug 13, 2025 | -$0.30 | -$0.30 | +0.0% | $290,000 |
| May 12, 2025 | -$0.25 | -$0.28 | +10.7% | $342,000 |
| Mar 26, 2025 | -$0.57 | -$0.26 | -119.2% | $234,000 |
| Nov 12, 2024 | -$0.21 | -$0.21 | +0.0% | $369,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 738.37× | — | — | Bottom 4% |
| Free-cash-flow yield | -38.50% | — | — | Bottom 12% |
| Earnings yield | -56.52% | — | — | Bottom 13% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -5.1%
- 200-day average slope (20 days)
- +1.3%
- Distance from 50-day average
- -7.2%
- Distance from 200-day average
- -23.5%
- RSI (14)
- 46.6
- Relative volume
- 1.13×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 61.4%
- Volatility vs own 5-year history
- 13th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.54
- Correlation with S&P 500
- 0.24
- Current drawdown from 1-year high
- -51.2%
- Maximum drawdown, 3 years
- -90.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 20, 2021 | Apr 8, 2025 | -93.1% | 1059 days | Not yet recovered |
| Sep 30, 2020 | Nov 20, 2020 | -38.1% | 37 days | 30 days (Jan 6, 2021) |
| Jan 11, 2021 | Jan 12, 2021 | -11.8% | 1 days | 3 days (Jan 15, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $314.8M
- EPS, diluted (TTM)
- -$1.56
- Revenue (TTM)
- $366,000
- 52-week range
- $1.96 – $6.16
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $10.8M | $5.4M | $1.4M | $1.5M | $0 |
| Gross profit | $4.6M | $2.4M | $1.4M | -$852,000 | $0 |
| Operating income | -$7.4M | -$9.1M | -$40.9M | -$66.8M | -$113.6M |
| Net income | -$7.3M | -$10.8M | -$46.5M | -$79.3M | -$103.1M |
| EPS (diluted) | -$0.50 | -$0.60 | -$0.85 | -$1.23 | -$1.40 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $369,000 | $290,000 | $209,000 | $0 | $76,000 | $81,000 |
| Net income | -$15.1M | -$40.2M | -$15.1M | -$21.5M | -$26.0M | -$37.5M | -$26.2M | -$26.8M |
| EPS (diluted) | -$0.21 | -$18.84 | -$0.21 | -$0.30 | -$0.35 | -$0.50 | -$0.35 | -$0.36 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$7.7M | -$10.4M | -$36.9M | -$18.3M | -$82.5M |
| Capital expenditure | -$266,000 | -$282,000 | -$1.1M | -$54.4M | -$12.7M |
| Free cash flow | -$8.0M | -$10.7M | -$38.0M | -$72.7M | -$95.2M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $56,000 | $0 | $918,000 | $289.4M | $10.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $236.9M
- Total assets
- $392.0M
- Total liabilities
- $68.2M
- Total debt
- $4.0M
- Net debt
- -$44.5M
- Shareholders’ equity
- $323.9M
As of Jun 30, 2026 (filed Aug 10, 2026).
Short interest
- Shares sold short
- 22,806,291
- Days to cover
- 16.85
- Change vs previous report
- -2.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jun 17, 2024
- 1-for-10
- Aug 17, 2005
- 1-for-30
- Jul 6, 1988
- 1-for-20